Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages

International Journal of Antimicrobial Agents

Volumn 48, Issue 1, 2016, Pages 69-77

  Samantaray, Sweta ^a   Correia, Joao N ^a   Garelnabi, Mariam ^a   Voelz, Kerstin ^a   May, Robin C ^a   Hall, Rebecca A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticryptococcal therapy; Cryptococcus neoformans; Drug screening; Fendiline; Intracellular proliferation; Macrophages

Indexed keywords

FENDILINE; ANTIFUNGAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CELL DENSITY; CELL DIVISION; CELL KILLING; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; FUNGAL MEMBRANE; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; HIGH THROUGHPUT SCREENING; HOST CELL; IN VITRO STUDY; LIVE CELL IMAGING ASSAY; MACROPHAGE; MOUSE; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; MICROBIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTIFUNGAL AGENTS; CELL LINE; CELL SURVIVAL; CRYPTOCOCCUS NEOFORMANS; CYTOLOGICAL TECHNIQUES; DRUG EVALUATION, PRECLINICAL; MACROPHAGES; MICE;

EID: 84973461712     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.04.018     Document Type: Article

References (38)

1. [1] Velagapudi, R., Hsueh, Y.P., Geunes-Boyer, S., Wright, J.R., Heitman, J., Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 77 (2009), 4345–4355.
2. [2] Park, B.J., Wannemuehler, K.A., Marston, B.J., Govender, N., Pappas, P.G., Chiller, T.M., Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23 (2009), 525–530.
3. [3] Rajasingham, R., Rolfes, M.A., Birkenkamp, K.E., Meya, D.B., Boulware, D.R., Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med, 9, 2012 e1001316.
4. [4] Vidal, J.E., Penalva de Oliveira, A.C., Dauar, R.F., Boulware, D.R., Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis 17 (2013), 353–362.
5. [5] Warkentien, T., Crum-Cianflone, N.F., An update on Cryptococcus among HIV-infected patients. Int J STD AIDS 21 (2010), 679–684.
6. [6] Feldmesser, M., Kress, Y., Novikoff, P., Casadevall, A., Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun 68 (2000), 4225–4237.
7. [7] Tucker, S.C., Casadevall, A., Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci USA 99 (2002), 3165–3170.
8. [8] Voelz, K., Lammas, D.A., May, R.C., Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun 77 (2009), 3450–3457.
9. [9] Smith, L.M., Dixon, E.F., May, R.C., The fungal pathogen Cryptococcus neoformans manipulates macrophage phagosome maturation. Cell Microbiol 17 (2015), 702–713.
10. [10] Davis, M.J., Eastman, A.J., Qiu, Y., Gregorka, B., Kozel, T.R., Osterholzer, J.J., et al. Cryptococcus neoformans-induced macrophage lysosome damage crucially contributes to fungal virulence. J Immunol 194 (2015), 2219–2231.
11. [11] Ma, H., Croudace, J.E., Lammas, D.A., May, R.C., Expulsion of live pathogenic yeast by macrophages. Curr Biol 16 (2006), 2156–2160.
12. [12] Alvarez, M., Casadevall, A., Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol 16 (2006), 2161–2165.
13. [13] World Health Organization, Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2011, WHO, Geneva, Switzerland.
14. [14] Perfect, J.R., Dismukes, W.E., Dromer, F., Goldman, D.L., Graybill, J.R., Hamill, R.J., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 291–322.
15. [15] Pasqualotto, A.C., Amphotericin B: the higher the dose, the higher the toxicity. Clin Infect Dis, 47, 2008, 1110.
16. [16] Butts, A., DiDone, L., Koselny, K., Baxter, B.K., Chabrier-Rosello, Y., Wellington, M., et al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell 12 (2013), 278–287.
17. [17] Vermes, A., Guchelaar, H.-J., Dankert, J., Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46 (2000), 171–179.
18. [18] Voelz, K., Johnston, S.A., Rutherford, J.C., May, R.C., Automated analysis of cryptococcal macrophage parasitism using GFP-tagged cryptococci. PLoS ONE, 5, 2010 e15968.
19. [19] Zhang, J.-H., Chung, T.D.Y., Oldenburg, K.R., A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4 (1999), 67–73.
20. [20] Gao, Q., Wang, Z., Liu, Z., Li, X., Zhang, Y., Zhang, Z., et al. A cell-based high-throughput approach to identify inhibitors of influenza A virus. Acta Pharm Sin B 4 (2014), 301–306.
21. [21] Kinchen, J.M., Ravichandran, K.S., Phagosome maturation: going through the acid test. Nat Rev Mol Cell Biol 9 (2008), 781–795.
22. [22] Swanson, M.S., Fernandez-Moreia, E., A microbial strategy to multiply in macrophages: the pregnant pause. Traffic 3 (2002), 170–177.
23. [23] Thi, E.P., Lambertz, U., Reiner, N.E., Sleeping with the enemy: how intracellular pathogens cope with a macrophage lifestyle. PLoS Pathog, 8, 2012 e1002551.
24. 2+ movement in hepatoma cells. Hum Exp Toxicol 20 (2001), 359–364.
25. 2+-triggered cell death in human oral cancer cells. Hum Exp Toxicol 28 (2009), 41–48.
26. 2+ in rabbit corneal epithelial cells. Life Sci 71 (2002), 1071–1079.
27. [27] Zhai, B., Zhou, H., Yang, L., Zhang, J., Jung, K., Giam, C.-Z., et al. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother 65 (2010), 931–938.
28. [28] Liu, W., Li, L.P., Zhang, J.D., Li, Q., Shen, H., Chen, S.M., et al. Synergistic antifungal effect of glabridin and fluconazole. PLoS ONE, 9, 2014 e103442.
29. [29] Stanley, S.A., Barczak, A.K., Silvis, M.R., Luo, S.S., Sogi, K., Vokes, M., et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog, 10, 2014 e1003946.
30. [30] Varela, R.E.M., Muñoz, D.L., Robledo, S.M., Kolli, B.K., Dutta, S., Chang, K.P., et al. Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. Exp Parasitol 122 (2009), 134–139.
31. [31] van der Hoeven, D., Cho, K., Ma, X., Chigurupati, S., Parton, R.G., Hancock, J.F., Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol 33 (2013), 237–251.
32. [32] Beckmann, N., Sharma, D., Gulbins, E., Becker, K.A., Edelmann, B., Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons. Front Physiol, 5, 2014, 331.
33. [33] Kornhuber, J., Tripal, P., Reichel, M., Terfloth, L., Bleich, S., Wiltfang, J., et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure−property−activity relation model. J Med Chem 51 (2008), 219–237.
34. [34] Wang, X., Zhu, S., Pei, Z., Drozda, M., Stavrovskaya, I.G., Del Signore, S.J., et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci 28 (2008), 9473–9485.
35. [35] Krysan, D.J., Toward improved anti-cryptococcal drugs: novel molecules and repurposed drugs. Fungal Genet Biol 78 (2015), 93–98.
36. [36] Regenthal, R., Krueger, M., Koeppel, C., Preiss, R., Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 15 (1999), 529–544.
37. [37] Gupta, S., Salam, N., Srivastava, V., Singla, R., Behera, D., Khayyam, K.U., et al. Voltage gated calcium channels negatively regulate protective immunity to Mycobacterium tuberculosis. PLoS ONE, 4, 2009 e5305.
38. [38] Adams Kristin, N., Takaki, K., Connolly Lynn, E., Wiedenhoft, H., Winglee, K., Humbert, O., et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145 (2011), 39–53.